3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2/3
1
Phase 2
1
Status
Terminated
1
Not yet recruiting
1
Completed
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Neoplasm Metastasis
3
Breast Neoplasms
2
Urologic Neoplasms
1
Urologic Diseases
1
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Stomatitis
1
Rectal Neoplasms
1
Pain, Postoperative
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Mucositis
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
98
Gemcitabine
70
Paclitaxel
59
Docetaxel
52
Carboplatin
49
Cisplatin
40
Nivolumab
39
Capecitabine
35
Pemetrexed
33
Fluorouracil
32
Bevacizumab
32
Cetuximab
31
130-nm albumin-bound paclitaxel
28
Trastuzumab
26
Irinotecan
24
Albumin-Bound Paclitaxel
24
Fulvestrant
22
Leucovorin
20
Oxaliplatin
18
Panitumumab
17
abemaciclib
16
Ipilimumab
16
Cyclophosphamide
15
cemiplimab
14
atezolizumab
14
Letrozole
14
palbociclib
12
Lapatinib
12
Drug Therapy
12
Doxorubicin
12
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
INDUSTRY
×
Neoplasm Metastasis
×
Water
×
Clear all
NCT07321847
2026-01-07
INJECTABL-3
Immunophotonics, Inc.
Phase 2/3
Not yet recruiting
717 enrolled
NCT04799249
2024-08-01
PRESERVE 2
G1 Therapeutics, Inc.
Phase 3
Completed
194 enrolled
NCT04863248
2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2
Terminated
10 enrolled
14 charts